Patents by Inventor James Breitenbucher
James Breitenbucher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250122172Abstract: The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders, including inflammatory and renal disorders.Type: ApplicationFiled: May 10, 2024Publication date: April 17, 2025Inventors: Venkataiah Bollu, James Breitenbucher, Alan Kaplan, Robert Lemus, Andrew Lindstrom, Troy Vickers, Michael Weinhouse, Mark E. Wilson, James Zapf
-
Publication number: 20250092047Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: ApplicationFiled: March 22, 2024Publication date: March 20, 2025Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Publication number: 20230192698Abstract: The invention provides a chemical entity of Formula (I): , wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: ApplicationFiled: June 27, 2022Publication date: June 22, 2023Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Publication number: 20230075774Abstract: The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders, including inflammatory and renal disorders.Type: ApplicationFiled: March 15, 2022Publication date: March 9, 2023Inventors: Venkataiah Bollu, James Breitenbucher, Alan Kaplan, Robert Lemus, Andrew Lindstrom, Troy Vickers, Michael Weinhouse, Mark E. Wilson, James Zapf
-
Patent number: 11279691Abstract: The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.Type: GrantFiled: May 28, 2019Date of Patent: March 22, 2022Assignee: Dart Neuroscience LLCInventors: Venkataiah Bollu, James Breitenbucher, Alan Kaplan, Robert Lemus, Andrew Lindstrom, Troy Vickers, Michael Weinhouse, Mark E. Wilson, James Zapf
-
Patent number: 11186582Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: GrantFiled: November 25, 2019Date of Patent: November 30, 2021Assignee: Dart Neuroscience, (Cayman) LTD.Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Publication number: 20200095256Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: ApplicationFiled: November 25, 2019Publication date: March 26, 2020Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Publication number: 20200024259Abstract: The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders, including inflammatory and renal disorders.Type: ApplicationFiled: May 28, 2019Publication date: January 23, 2020Inventors: Venkataiah Bollu, James Breitenbucher, Alan Kaplan, Robert Lemus, Andrew Lindstrom, Troy Vickers, Michael Weinhouse, Mark E. Wilson, James Zapf
-
Patent number: 10501465Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: GrantFiled: February 26, 2018Date of Patent: December 10, 2019Assignee: Dart Neuroscience (Cayman) Ltd.Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Patent number: 10376514Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: GrantFiled: October 18, 2018Date of Patent: August 13, 2019Assignee: Dart Neuroscience (Cayman) Ltd.Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael I. Weinhouse
-
Patent number: 10239882Abstract: The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: GrantFiled: November 3, 2015Date of Patent: March 26, 2019Assignee: DART NEUROSCIENCE (CAYMAN) LTD.Inventors: Amy Lynn Allan, James Breitenbucher, Laurent Gomez, Terence Patrick Keenan, Robert Lemus, Kiev Ly, Tami Jo Marrone
-
Publication number: 20190046535Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: ApplicationFiled: October 18, 2018Publication date: February 14, 2019Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael I. Weinhouse
-
Publication number: 20180346448Abstract: The invention provides a chemical entity of Formula (I), and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting PDE4, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating treating peripheral disorders, including inflammatory and renal disorders.Type: ApplicationFiled: June 6, 2018Publication date: December 6, 2018Inventors: Venkataiah Bollu, James Breitenbucher, Alan Kaplan, Robert Lemus, Andrew Lindstrom, Troy Vickers, Michael Weinhouse, Mark E. Wilson, James Zapf
-
Patent number: 10105367Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: GrantFiled: December 29, 2016Date of Patent: October 23, 2018Assignee: DART NEUROSCIENCE (CAYMAN) LTD.Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael Weinhouse
-
Patent number: 10092575Abstract: Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: GrantFiled: November 17, 2016Date of Patent: October 9, 2018Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers
-
Publication number: 20180282338Abstract: The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: ApplicationFiled: November 3, 2015Publication date: October 4, 2018Inventors: Amy Lynn Allan, James Breitenbucher, Laurent Gomez, Terence Patrick Keenan, Robert Lemus, Kiev Ly, Tami Jo Marrone
-
Publication number: 20180179216Abstract: The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: ApplicationFiled: February 26, 2018Publication date: June 28, 2018Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Patent number: 9956224Abstract: Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: GrantFiled: December 29, 2016Date of Patent: May 1, 2018Assignee: DART NEUROSCIENCE (CAYMAN) LTD.Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers, Michael Weinhouse
-
Patent number: 9932345Abstract: The invention provides a chemical entity of Formula (I) wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.Type: GrantFiled: April 22, 2015Date of Patent: April 3, 2018Assignee: Dart NeuroScience (Cayman) Ltd.Inventors: James Breitenbucher, Graeme Freestone, Laurent Gomez, Robert Lemus, Kiev Ly, Margaret McCarrick, William Vernier, Troy Vickers
-
Publication number: 20170209459Abstract: Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.Type: ApplicationFiled: November 17, 2016Publication date: July 27, 2017Inventors: Bryan Branstetter, James Breitenbucher, Brian Dyck, Laurent Gomez, Andrew Richard Hudson, Tami Jo Marrone, Marco Peters, Troy Vickers